Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis lactis VES002
- Development stage
- Unknown
- Lead developer
- Ceres Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis lactis VES002 is a specific strain of probiotic bacterium from the Bifidobacterium genus, used as a live biotherapeutic in dietary supplements. It is characterized by high digestive tract resistance and strong mucosal adhesion. In human clinical studies, VES002 (LMG P-28149) was administered with fructo-oligosaccharides to evaluate its impact on intestinal transit, bowel movements, and gut microbiota composition in subjects with infrequent bowel movements. The mechanism involves modulation of the gut microbiome, improvement of intestinal barrier function, and enhancement of mucosal immunity, primarily through effects on tight junction genes such as zonula occludens 1 and Toll-like receptor 2. Its probiotic activity likely includes restoration of normal microbial balance and immunomodulation by increasing IgA secretion and supporting barrier integrity[2].
- Other names
- bifidobacterium animalis lactis VES002bifidobacterium animalis subsp. lactis VES002bifidobacterium animalis lactis LMG P-28149
02
Targets
TLR2 (Toll-like Receptor 2)TJP1 (Tight junction protein 1 (ZO-1))Peyer's patch B-cell IgA secretion pathway
Beyond the preview
Go deeper on bifidobacterium animalis lactis VES002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis lactis VES002.